A potential advantage of T-DXd is the possibility of activity in HER2-low LM in patients with breast cancer, and even potential for activity in LM from other solid tumors, given the broad extracranial efficacy profile reported to date. The gene discussed is ERBB2; the disease is breast carcinoma.